Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Biopharmaceutical companies are awash with more cash than at any time in the sector’s history. But they are scrambling to prepare for the drought of a COVID-19-related recession.
US venture funding for the sector reached a peak of $5.5 billion in the first three months of 2020, according to PitchBook. But if COVID-19-linked disruption to employment, travel, global supply chains and economies endures longer than the six months written into some investors’ plans, even a well-capitalized sector must prepare for rocky times ahead.